Security
NorthView Acquisition Corporation Red Wt Exp 08/02/2027 · NVACW
NVACWOTCWarrantCurrentCIK 1859807Updated Oct 28, 2026
Name history
NorthView Acquisition Corp · through Jul 15, 2025
NVACW price & chart
Loading TradingView…
OTC:NVACW on TradingView ↗About the company
Profusa was incorporated in the state of California on May 11, 2009 and operates as a digital health technology company based in Berkeley, California. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empowers the individual with the ability to monitor their unique body chemistry. Profusa has invested over the last twelve years more than $100 million from sophisticated venture investors as well as the most sophisticated research institutions in the U.S. (including approximately $30 million from Defense Advance Research Projects Agency (“DARPA”) and the National Institutes of Health (“NIH”)) to develop a unique biosensor platform that is easily injected subcutaneously to provide, for the first time, real-time, individual biochemistry, that is cost effective while functioning for more than six times longer than known best in class solutions on the market today.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
4 filing
4 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 4,250,000Source | 8,783,792Source | 1,042,000Source | 1,962,416Source | 8,589,945Source | 862,000Source | 1,983,584Source | 8,499,232Source | 3,775,000Source | 8,391,697Source | 10,884,675Source | 194,736,486Source |
| Property, Plant and Equipment, NetUSD | — | — | 84,000Source | — | — | 13,000Source | — | — | 8,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,009,000Source | 533Source | — | — | 6,496Source | 375,000Source | — | 5,314Source | 1,778,000Source | 16,204Source | 4,519Source | — |
| Assets, CurrentUSD | 4,195,000Source | 681,943Source | 841,000Source | 687,867Source | 113,521Source | 662,000Source | 63,183Source | 66,064Source | 3,764,000Source | 60,862Source | 1,576,347Source | 511,704Source |
| Prepaid Expense and Other Assets, CurrentUSD | 214,000Source | 38,945Source | 122,000Source | — | 40,500Source | 287,000Source | 14,193Source | 60,750Source | 541,000Source | 14,166Source | 6,750Source | 318,218Source |
| Other Assets, NoncurrentUSD | 55,000Source | — | 47,000Source | — | — | 41,000Source | — | — | 3,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 38,210,000Source | 5,818,119Source | 28,169,000Source | 23,142,121Source | 5,114,056Source | 29,060,000Source | 14,298,791Source | 4,625,856Source | 30,433,000Source | 13,011,056Source | 5,091,777Source | 1,830,478Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 4,000Source | 519Source | — | 519Source | 519Source | — | 519Source | 519Source | — | 519Source | 519Source | 519Source |
| Additional Paid in CapitalUSD | 118,250,000Source | — | 145,865,000Source | — | — | 136,039,000Source | — | — | 134,123,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -152,214,000Source | -5,175,781Source | -172,992,000Source | -22,510,739Source | -5,075,539Source | -164,237,000Source | -14,298,283Source | -4,496,722Source | -160,781,000Source | -12,957,266Source | -3,459,829Source | -619,995Source |
| Stockholders' Equity Attributable to ParentUSD | -33,960,000Source | -116,958,000Source | -27,127,000Source | -124,182,000Source | -5,075,020Source | -28,198,000Source | -121,916,000Source | -4,496,203Source | -26,658,000Source | -12,956,747Source | -3,459,310Source | -619,476Source |
| Liabilities and EquityUSD | 4,250,000Source | 8,783,792Source | 1,042,000Source | 1,962,416Source | 8,589,945Source | 862,000Source | 1,983,584Source | 8,499,232Source | 3,775,000Source | 8,391,697Source | 10,884,675Source | 194,736,486Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 23,540,000Source | 5,165,460Source | 28,167,000Source | 16,180,421Source | 4,156,822Source | 29,020,000Source | 13,254,536Source | 3,964,494Source | 22,258,000Source | 12,314,886Source | 4,921,477Source | 935,751Source |
| Accounts Payable, CurrentUSD | 6,982,000Source | — | 7,855,000Source | — | — | 8,309,000Source | — | — | 7,345,000Source | — | — | — |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 13,661Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,848,000Source | 726,980Source | 6,223,000Source | 1,744,538Source | 704,831Source | 6,180,000Source | 933,870Source | 614,287Source | 5,981,000Source | 684,483Source | 449,114Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 36,940Source |
| Redeemable Noncontrolling Interest, Equity, Common, Carrying AmountUSD | — | 595,439Source | — | — | — | — | — | — | — | — | 1,565,078Source | — |
| Operating Lease, Right-of-Use Asset | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Additional Paid in Capital, Common Stock | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 187,000Source | 5,000Source | 891,000Source | — | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 964,000Source | 764,000Source | 3,560,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -5,529,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,576,000Source | -537,000Source | -16,248,000Source | -1,296,812Source | -2,064,860Source | -581,189Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 1,145,000Source | 6,490,359Source | -2,008,000Source | 2,967,987Source | 185,599,914Source | 33,447Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,000Source | — | 8,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | 6,510,830Source | — | 3,248,878Source | 184,845,836Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 28,000Source | 365,000Source | 19,843,000Source | -1,659,490Source | -183,724,021Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,009,000Source | 140,000Source | 719,000Source | 39,000Source | 375,000Source | 19,000Source | 1,778,000Source | 16,204Source | 4,519Source | 193,486Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 296,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 617,000Source | 12,000Source | 188,000Source | 82,000Source | 187,000Source | 5,000Source | 891,000Source | — | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | 3,294,000Source | — | — | — |
| Financing Interest ExpenseUSD | — | — | 1,443,000Source | — | 2,410,000Source | — | 60,000Source | — | 2,574,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 258,000Source | -320,000Source | — | — | 1,392,000Source | — | -3,378,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 20,987,000Source | 767,000Source | 1,722,000Source | 610,000Source | 2,860,000Source | 990,000Source | 24,902,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 19,499Source | — | 2,386Source | — | 19,352Source | — | 80,513Source | 456,790Source | 499,211Source |
| InterestExpenseNonoperatingUSD | — | — | 169,000Source | 1,073,000Source | 21,000Source | 1,193,000Source | 18,000Source | 1,135,000Source | 2,521,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 108,750Source | — | 15,159Source | — | 79,925Source | — | 425,416Source | 2,248,538Source | 2,579,268Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -22,192,000Source | -2,497,000Source | -8,755,000Source | -2,348,000Source | -3,456,000Source | -2,716,000Source | -35,823,000Source | -8,711,619Source | 1,161,910Source | 7,167,738Source |
| Noncash Merger Related CostsUSD | — | — | — | — | — | — | — | — | 500,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -483,000Source | -1,394,000Source | -6,210,000Source | -1,345,000Source | 550,000Source | -1,292,000Source | -8,117,000Source | -7,280,068Source | 3,127,383Source | — |
| Operating Costs and ExpensesUSD | — | — | — | 317,270Source | — | 967,084Source | — | 583,581Source | — | 1,351,038Source | 1,508,683Source | 1,270,554Source |
| Operating ExpensesUSD | — | — | 21,709,000Source | 1,178,000Source | 2,545,000Source | 1,003,000Source | 4,006,000Source | 1,424,000Source | 27,706,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 15,000Source | -1,000Source | 54,000Source | 1,000Source | 71,000Source | -1,000Source | 16,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | -7,701,178Source |
| Operating Lease, Expense | — | — | — | — | — | —Source | —Source | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Unrealized Gain (Loss) on Derivatives | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -21,709,000Source | -1,103,000Source | -2,545,000Source | -1,003,000Source | -4,006,000Source | -1,424,000Source | -27,706,000Source | -1,351,038Source | -1,508,683Source | -1,270,554Source |
| Other Nonoperating Income (Expense)USD | — | — | 15,000Source | -1,000Source | 54,000Source | 1,000Source | 71,000Source | -1,000Source | 16,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | 110,676Source | — | -8,194,490Source | — | -1,100,558Source | — | -8,631,106Source | 1,618,700Source | 7,666,949Source |
| Income Tax Expense (Benefit)USD | — | — | — | 19,499Source | — | 2,386Source | — | 19,352Source | — | 80,513Source | 456,790Source | 499,211Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -22,192,000Source | -2,497,000Source | -8,755,000Source | -2,348,000Source | -3,456,000Source | -2,716,000Source | -35,823,000Source | -8,711,619Source | 1,161,910Source | 7,167,738Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.7Source | -1.29Source | -151.8Source | -9,100.78Source | -2.05Source | -105.09Source | -107.01Source | -1.47Source | 0.12Source | 0.3Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.7Source | -1.29Source | -151.8Source | -9,100.78Source | -2.05Source | -105.09Source | -107.01Source | -1.47Source | 0.12Source | 0.3Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 31,731,118Source | 1,938,392Source | 57,676Source | 258Source | 1,688,107Source | 25,844Source | 334,762Source | 5,193,750Source | 5,193,750Source | 5,193,750Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 31,731,118Source | 1,938,392Source | 57,676Source | 258Source | 1,688,107Source | 25,844Source | 334,762Source | 5,193,750Source | 5,193,750Source | 5,193,750Source |
| Interest Expense (non-operating)USD | — | — | 169,000Source | 1,073,000Source | 21,000Source | 1,193,000Source | 18,000Source | 1,135,000Source | 2,521,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | 3,294,000Source | — | — | — |
| Financing Interest ExpenseUSD | — | — | 1,443,000Source | — | 2,410,000Source | — | 60,000Source | — | 2,574,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 20,987,000Source | 767,000Source | 1,722,000Source | 610,000Source | 2,860,000Source | 990,000Source | 24,902,000Source | — | — | — |
| Interest Income, OperatingUSD | — | — | — | — | — | — | — | — | — | — | — | 8,937,503Source |
| Investment Income, InterestUSD | — | — | — | 108,750Source | — | 15,159Source | — | 79,925Source | — | 425,416Source | 2,248,538Source | 2,579,268Source |
| Nonoperating Income (Expense)USD | — | — | -483,000Source | -1,394,000Source | -6,210,000Source | -1,345,000Source | 550,000Source | -1,292,000Source | -8,117,000Source | -7,280,068Source | 3,127,383Source | — |
| Operating Costs and ExpensesUSD | — | — | — | 317,270Source | — | 967,084Source | — | 583,581Source | — | 1,351,038Source | 1,508,683Source | 1,270,554Source |
| Operating ExpensesUSD | — | — | 21,709,000Source | 1,178,000Source | 2,545,000Source | 1,003,000Source | 4,006,000Source | 1,424,000Source | 27,706,000Source | — | — | — |
| Other Operating IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | 722,000Source | 411,000Source | 823,000Source | 393,000Source | 1,146,000Source | 434,000Source | 2,804,000Source | — | — | — |
| Total Revenue | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Interest Expense, Debt | — | — | — | — | — | —Source | — | —Source | — | — | — | — |
| Interest Income, Other | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Operating Lease, Expense | — | — | — | — | — | —Source | —Source | — | — | — | — | — |
| Other General and Administrative Expense | — | — | —Source | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-295364
Registration 333-293179
Registration 333-293451
Filing attachments
ea030512101ex99-1.htm · 8-K · 2026-09-15
EX-99.1 2 ea030512101ex99-1.htm PRESS RELEASE DATED SEPTEMBER 14, 2026 Exhibit 99.1 Profusa, Inc. Receives Nasdaq Compliance Determination Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Pr…
Read attachment ↗ea030394501ex99-1.htm · 8-K · 2026-08-31
EX-99.1 2 ea030394501ex99-1.htm PRESS RELEASE Exhibit 99.1 Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on August 14, 2026, following the effectiveness of the Company’s 1-for-4 reverse stock split, the Company had…
Read attachment ↗ea030281201ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 ea030281201ex99-1.htm PRESS RELEASE Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working capital obtained to fund operations for near term PCAOB audited 2024 and…
Read attachment ↗ea030001701ex99-1.htm · 8-K · 2026-07-31
EX-99.1 4 ea030001701ex99-1.htm PRESS RELEASE ISSUED ON JULY 31, 2026 Exhibit 99.1 Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligat…
Read attachment ↗ea029883201ex99-1.htm · 8-K · 2026-07-27
EX-99.1 2 ea029883201ex99-1.htm PRESS RELEASE DATED JULY 27, 2026 Exhibit 99.1 Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and …
Read attachment ↗ea029713001ex99-1.htm · 8-K · 2026-07-06
EX-99.1 3 ea029713001ex99-1.htm PRESS RELEASE DATED JULY 2, 2026 Exhibit 99.1 Profusa Announces 1-for-25 Reverse Stock Split BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporati…
Read attachment ↗